Hepatic Artery Infusion Therapy for Colorectal Cancer that has Spread to the Liver

    Hepatic Artery Infusion (HAI) therapy is an FDA-approved cancer treatment that delivers medicine continuously and directly to tumors in the liver, using an implantable pump. HAI therapy is used for patients living with colorectal cancer that has spread to the liver.

    Is HAI therapy right for me?

    How does the pump work?

    The Intera 3000 HAI Pump is surgically implanted under the skin in the abdomen. The pump is activated by body heat, sending medicine from the pump through a catheter connected to the hepatic artery and into the liver.

    What is the goal of HAI therapy?

    Clinical studies have shown that HAI therapy may reduce the size of tumors in the liver, improve disease control in the liver, increase chances of liver resection, prevent recurrence, and improve chances of survival.1,2,3,4

    How does HAI compare to systemic chemotherapy?

    Because the HAI pump connects directly to the liver, the treatment does not need to go through the rest of the body to reach the liver. Unlike systemic chemotherapy, HAI therapy limits potential side effects throughout the body.

    Hepatic Artery Infusion: Learn how it works

    HAI video thumb

    Resources

    HAI Patient FAQ

    FAQs

    Read FAQs about getting and living with an HAI pump.

     

    HAI Webinar Thumb

    Webinar: Colorectal Liver Metastases: HAI Therapy and Exploring Your Options

    This webinar, hosted by Lindsey Glaspell from the Colorectal Cancer Alliance and featuring Dr. Nicholas Hornstein, a Medical Oncologist at the Northwell Health Cancer Institute, focused on hepatic artery infusion therapy (HAI) as a treatment option for colorectal cancer liver metastasis. Dr. Hornstein presented an overview of HAI therapy, explaining how it delivers chemotherapy directly to the liver through a surgically implanted pump.

     

    Daily activities grid

    Where can I find an HAI provider?

    There are numerous HAI centers across the United States, with more locations opening around the country.

    • To learn about an HAI provider near you, fill out this simple form.
    • A patient navigator at Intera Oncology, the pump’s manufacturer, will contact you to provide direct information about HAI therapy and help you find an HAI provider.

    Patient Testimonials

    Read stories of survivors living with the HAI pump.

    1. Kemeny N et al. N Engl J Med. 1999;341(27):2039-48. 

    2. Dhir M et al. Ann Surg Oncol. 2017;24(1):150-158.

    3. Groot Koerkamp B et al. J Clin Oncol. 2017;35(17):1938-1944. 

    4. Pak L et al. J Surg Oncol. 2018;117(4):634-643.

    The information provided here is for general informational purposes only and should not be considered as medical advice. Please consult with an HAI provider to determine your specific treatment plan and talk about the potential risks and benefits of the device. Individual results may vary.

    The Intera 3000 Hepatic Artery Infusion Pump is indicated for the continuous arterial administration of JND Therapeutics Floxuridine for Injection, USP, heparinized saline, and glycerin. The approved labeling for JND Therapeutics Floxuridine for Injection, USP stipulates the indications, contraindications, and warnings for use of the drug in the pump. The Intera 3000 Hepatic Artery Infusion Pump is contraindicated for use in patients with extensive extrahepatic disease or limited hepatic function. Possible adverse events of the pump are those potential risks associated with any implanted drug delivery device and include: catheter thrombosis, bolus path occlusion, vessel thrombosis, pump dislodgement, seroma, or recurrent hematoma, infection, extravasation, catheter shear, dislodgement or leakage, migration, arterial pseudoaneurysm, arterial dissection, and extrahepatic perfusion. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. Please review the full safety information at https://www.interaoncology.com/patients-caregivers/hai-therapy/safety-information.

    Top resources

    View all resources
    A close-up digital illustration of glowing blue DNA strands twisting through a dark blue background. Multiple double helixes appear at different depths, connected by a network of lighted nodes and lines.

    A blood test that sees what scans can't

    For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.

    Last updated
    A collage featuring a smiling woman with a chest infusion port, a medical team preparing for a procedure, and a close-up of an HAI pump used for liver-directed chemotherapy treatment.

    HAI therapy proves pivotal for pioneering patient

    When Helen was diagnosed with metastatic colorectal cancer, the biggest concern for her medical team was that her cancer had spread to her liver. One type of therapy, hepatic artery infusion, offered a path forward, but there was a catch. Nobody at her hospital had ever done it before. She'd have to be first.

    Last updated
    Dr. Mielke smiles while working in a research laboratory, wearing a white lab coat and blue gloves as she holds a pipette beside lab equipment.

    Where breakthroughs begin: Project Cure CRC spotlight on Dr. Lisa Mielke

    hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.

    Last updated